At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to ...
Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, ...
The bills would require insurers to cover germline multi-gene testing for inherited cancer risk and imaging with no out-of-pocket cost for patients.
The partners will use 4D Path's imaging-based Q-Plasia OncoReader in a Phase II trial testing doublet and triplet regimens comprising Trodelvy, Padcev, and Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results